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Edited by Veli-Pekka LehtoAbstract The eﬀects of progesterone derivatives on breast can-
cer development are still controversial, probably accounting for
their biphasic, opposed eﬀects on mammary cell-cycle regulation.
Here, we demonstrate in vitro that the growth-inhibitory eﬀects
of progesterone on breast cancer T-47D cells require the tran-
scriptional upregulation of the cyclin-dependent kinase inhibitor
p27Kip1 (p27) gene. A statistical analysis of human tumor biop-
sies further indicates that p27 mRNA levels correlate to proges-
terone receptor (PR) levels. Moreover, p27 gene expression is
inversely associated with tumor aggressiveness, and is a prognos-
tic factor of favorable disease outcome. Thus, progesterone
derivatives selectively activating the p27 gene promoter could
be promising drugs against breast cancer progression.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The steroid hormone progesterone is required for the termi-
nal growth and diﬀerentiation of the mammary gland [1]. In
clinical practice, the expression of progesterone receptor
(PR) with the estrogen receptor (ER) is currently assessed as
a predictive marker for favorable disease prognosis and for re-
sponse to hormonal therapy [2]. Moreover, prolonged syn-
thetic progestin administration is recommended in the
treatment of certain breast tumors [3]. For instance, second-
line high-dose therapy with certain synthetic progestins eﬀec-
tively suppresses the growth of metastatic breast cancers that
are ER- and PR-positive but display acquired resistance to
the anti-estrogen tamoxifen [3]. Nevertheless, the eﬀects of pro-Abbreviations: ER, estrogen receptor; PR, progesterone receptor; p21,
p21Cip1/WAF1; p27, p27Kip1; HPG, histoprognostic grading; HRT,
hormone replacement therapy; OS, overall survival; PRE, progester-
one responsive element
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doi:10.1016/j.febslet.2005.08.084gesterone and its derivatives – notably when administrated in
hormone replacement therapies (HRTs) or in oral contracep-
tives – on breast cancer risk are still controversial in epidemi-
ological studies [4,5].
Control of cell-cycle progression appears to occur primarily
through the regulation of the retinoblastoma gene product
(pRB) phosphorylation – which represents the critical check-
point of the G1ﬁ S transition – by speciﬁc ‘‘cyclin-dependent
kinases’’ (CDKs) [6]. CDKs are constitutively expressed, and
interactions with the transiently expressed cyclins and ‘‘CDK
inhibitors’’ (CDKIs) activate and inhibit their activity, respec-
tively. Thus, regulation of the expression of these cyclins and
CDKIs acting in G1 is a key event in the control of cell prolif-
eration by a variety of growth signalling factors including ste-
roid hormones [6]. Notably, progestin-induced growth arrest
of T-47D breast cancer cells is related to an increased protein
abundance of the CDKIs p21Cip1/Waf1 (p21), p27Kip1 (p27) as
well as p18INK4C and changes in the associations formed with
the diﬀerent G1 CDK complexes leading to the downregula-
tion of their activity [7–9].
Induction of p27 protein expression has been demon-
strated both to mediate G1 cell-cycle arrest through inhibi-
tion of cyclin E/CDK2 complexes and to constitute a
molecular switch that facilitates diﬀerentiation [9–12]. Fur-
thermore, recent in vitro reports have associated the ability
of progestins to inhibit mammary cancer cell proliferation
and to induce the cell diﬀerentiation program [8,13,14].
However, whereas it has previously been demonstrated that
progesterone-activated PR regulates transcription of the p21
gene by interacting with Sp1 and p300 at proximal
Sp1-binding sites [15], the mechanisms involved in the pro-
gesterone-dependent p27 upregulation has not yet been
investigated. In the present study, we ﬁrst veriﬁed using a
siRNA approach that p27 plays a key role in mediating
growth-inhibitory action of progesterone on mammary
breast carcinoma T-47D cells and demonstrated that proges-
terone up-regulates p27 expression at transcriptional level. In
addition, we demonstrated that p27 mRNA levels are posi-
tively associated with PR protein expression levels and ap-
peared as a prognostic indicator of favourable patient
outcome. Taken together, our results indicate that the
control of p27 gene expression may play a key role in the
regulation of breast cancer cell growth, notably by the pro-
gesterone.ation of European Biochemical Societies.
Fig. 1. Inhibition of T-47D cell proliferation by progesterone requires
p27 gene expression. p27 mRNA levels (A), DNA content (B) as well
as protein abundance of p27 and pRB phosphorylated at Ser807/811
(C) were determined 4 days after siRNA transfection. All values are
expressed relative to vehicle-incubated control siRNA-transfected cells
arbitrarily set as 1. Cellular DNA content and mRNA levels are
means ± S.D. (n = 3). Diﬀerent letters indicate statistically signiﬁcant
diﬀerences between values. p27 and ppRB-Ser807/811 levels normal-
ized to b-actin levels are indicated below the blots.
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2.1. Cell culture assays and molecular analyses
Human T-47D breast cancer cells were obtained from American
Type Culture Collection (ATCC) and cultured as recommended in a
medium supplemented with 10% fetal calf serum, L-glutamine
(2 mM), and antibiotic gentamycin (1%). Progesterone was added daily
to the medium at a concentration of 30 nM (i.e., 10-fold EC50 value
for PR [16]) as previously performed [7].
Small interfering RNA (siRNA) assays were performed as described
previously [17] with p27 (Ambion, siRNAs nos. 14072 and 14165) or
control (Qiagen) siRNAs (10 nM). Experiments shown in the manu-
script have been performed with the p27 siRNA no. 14072. p27 expres-
sion knockdown using the siRNA no. 14165 led to a 42% decrease in
p27 mRNA levels and comparable eﬀects on cell proliferation as well
as pRB phosphorylation as obtained with siRNA-no. 14072.
Reverse transcription and quantitative PCR were performed as de-
scribed in [17] from total RNA from T-47D cells or breast cancer tis-
sues (see below). mRNA levels were normalized to 28S RNA levels
because of its stability during cell-cycle progression.
Cellular DNA content was analyzed following nuclear DNA staining
using the ﬂuorochrome 3,5-diaminobenzoicacid free acid (DABA) as
described previously [17].
Transient transfection assays. T-47D cells were seeded for 24 h in 24-
well plates at a density of 1 · 105 cells per well. Cells were transfected
with FuGENE 6 (Roche Molecular Biochemicals) at a ratio of 3:1 Fu-
GENE:DNA. The p27Luc reporter plasmids (100 ng) [18], comprising
the indicated 5 0-ﬂanking DNA regions of the p27 gene subcloned in the
luciferase reporter vector pGL2, were cotransfected with the indicated
amounts of expression vectors and the internal control Renilla lucifer-
ase reporter plasmid pRL-Null (10 ng). The quantity of plasmids in the
transfection mixture was normalized with empty pcDNA3 vector. 12 h
after transfection, medium was changed and cells were incubated for
an additional 34 h with progesterone or vehicle. Cells were then har-
vested and cell lysates (20 ll) were assayed for luciferase activity.
Western blot analyses were achieved from 30 lg of whole cell protein
extracts. The anti-ppRB-Ser807/811 (9308, Cell Signalling) – raised
against a pRB peptide phosphorylated on the Ser807/811 residue –
anti-p27 (K25020, Transduction Laboratories) and anti-b-actin (sc-
7210, Santa Cruz) – for normalization of protein levels – antibodies
were used. Relative abundances were quantiﬁed with SCANWISE
and Perfect-IMAGE V-5.3 (CLARA VISION, France) softwares.
The blots represent typical results of three independent experiments.
Chromatin immunoprecipitation (ChIP) assays were performed as
described in [17]. T-47D cells were incubated with either progesterone
or with ethanol (vehicle) in 0.2% BSA-RPMI during 2 h 30 min before
lysis.
Statistical analyses were performed using the non-parametric Krus-
kal–Wallis test. Values are expressed as means ± S.D. of a representa-
tive experiment performed in triplicate (n = 3) which was repeated at
least three times.
The pilot statistical study on human breast cancer biopsies was per-
formed as described in [17]. Among the tumor samples, 72% and
71% were ER and PR positive, respectively, and the classical correla-
tion between ER and PR expression (P < 0.001, r = 0.621) was ob-
served. Overall survival (OS) and relapse free survival were studied
by Kaplan Meier method analysis. Comparison between curves was
carried out by the log rank test. The RNA from the normal human
mammary gland was obtained from BD Biosciences, France.3. Results
3.1. Progesterone inhibits breast cancer G1ﬁ S cell-cycle
transition by inducing p27 gene expression
To ﬁrstly decipher the contribution of p27 in mediating the
eﬀect of progesterone on mammary cell growth, a siRNA ap-
proach which targets p27 was used (Fig. 1). In agreement with
previous studies [7,8], a decrease of cell proliferation associated
with a decrease of pRB phosphorylation were provoked by
progesterone in control-transfected cells. Strikingly, these ef-
fects were nearly entirely eliminated in cells transfected withp27 siRNA, demonstrating that p27 expression is required
for the negative control of progesterone on mammary cell
growth.
To analyze the molecular mechanisms involved in the eﬀects
of progesterone, p27 gene expression was measured in T-47D
cells (Fig. 2A). Treatment with progesterone increased p27
mRNA in a time-dependent manner as early as 6 h after initi-
ation of the treatment (Fig. 2A). In correlation, p27 protein
levels increased following progesterone treatment and reached
their maximum as early as after 12 h, a time-point preceding
the cell-cycle arrest observed after 36 h. By contrast, progester-
one treatment did not aﬀect either p27 mRNA levels or the cell
proliferation rate of MDA-MB-231 cells, which do not express
PR [19] (Fig. 2B). Thus, progesterone may induce p27 protein
expression, at least in part, through PR-dependent upregula-
tion of p27 gene transcription.
3.2. Progesterone-activated PR enhances p27 promoter activity
by binding to a multiprotein complex formed with Sp1 and
p300 on the 549/511 proximal p27 promoter
To further decipher whether p27 is a target gene of proges-
terone-activated PR, luciferase reporter constructs controlled
by either the full-length 3568 bp promoter or 5 0-deleted
Fig. 2. Progesterone induces p27 gene expression and inhibits cell proliferation in T-47D (A), but not in MDA-MB-231 (B) cells. Cells treated for the
indicated periods of time with progesterone (30 nM) or vehicle were harvested for quantitative RT-PCR, DNA content and Western-blot assays. p27/
28S RNA levels and cellular DNA content are expressed relative to time 6 h, arbitrarily set as 1. *P 6 0.05; **P 6 0.01; ***P 6 0.001 vs. vehicle-
incubated cells. Numbers under the Western-blot of p27 indicate the amounts of p27/b-actin protein expressed relative to the levels in cells at time 0 h,
arbitrarily set as 1. In B, no signiﬁcant diﬀerence was found between progesterone-treated and untreated cells.
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into T-47D cells treated or not with progesterone (Fig. 3A).
Progesterone treatment signiﬁcantly induced (3-fold) 3568
p27 promoter activity, demonstrating that progesterone regu-
lates p27 gene expression at the transcriptional level. More-
over, progesterone-dependent p27 promoter activation was
maintained upon 5 0-deletion to -549bp, but not upon further
deletion to 511 bp. The 549/511 DNA region contains
two Sp1-binding sites (denoted Sp1-1 and Sp1-2, respectively)
as well as a CCAAT box, which have been previously identi-
ﬁed as crucial elements for the regulation of this gene[18,20,21]. Interestingly, the induction of p27 promoter activity
following progesterone treatment was either completely elimi-
nated or reduced by mutation of Sp1-1 and Sp1-2 sites, respec-
tively, but it was not aﬀected by mutation of the CCAAT box.
Since Owen et al. have previously demonstrated that proges-
terone-activated PR interacts with Sp1 and p300 at proximal
Sp1-binding sites to regulate transcription of the p21 gene
[15], we further analyzed the putative PR-dependent p27 pro-
moter activation by p300 (Fig. 3B). In fact, transfection of
p300 enhanced progesterone-induced p27 promoter activity
through these proximal Sp1-binding sites (Fig. 3B).
Fig. 3. Progesterone-activated PR enhances p27 promoter activity through interaction with p300 at proximal Sp1-binding sites in T-47D cells. T-47D
cells were transiently co-transfected with the luciferase reporter constructs driven by the indicated p27 promoter deletion or mutation fragments
without (A) or with (B) the p300 expression vector. Results are represented as fold increase (means ± S.D.), with the luciferase activity levels of the
3558p27Luc reporter construct arbitrarily set as 1. The arrow indicates the transcription start site.
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ing elements by progesterone-activated PR, ChIP experiments
were performed (Fig. 4). In good agreement with previous ﬁnd-
ings [18], the genomic DNA region encompassing the Sp1-1 and
-2 binding sites was immunoprecipitated by the anti-Sp1 anti-
body. Moreover, in accordance with the results of the promoterreporter assays, the proximal Sp1-binding DNA element was
immunoprecipitated by the anti-PR and anti-p300 antibodies.
Overall, these results indicate that progesterone-activated
PR may cooperate with Sp1 and p300 to increase p27 gene
expression through the proximal Sp1-binding sites, with the
Sp1-1 site mediating the major response (Fig. 5).
Fig. 4. PR occupies in cell the p27 gene promoter at the proximal element that contains the Sp1-binding sites. Chromatin was immunoprecipitated
from T-47D cells incubated with progesterone. Immunoprecipitations were performed using antibodies directed against Sp1, p300 or PR. Controls
include PCRs done without DNA (H2O) or with non-precipitated genomic DNA (input), and immunoprecipitations performed without antibody (no
Ab) or with an irrelevant antibody (anti-HA). P: low background signal attributable to ethidium bromide staining of the PCR primers.
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Fig. 5. Model of progesterone regulation of the p27 promoter. Data
are consistent with a model in which progesterone-bound PR is
indirectly tethered to the promoter through Sp1 protein(s) bound to
both proximal Sp1 sites in a multiprotein complex that also includes
CBP/p300. The Sp1 site 1 is necessary for basal p27 transcription, and
both Sp1 sites are required for transcriptional upregulation by
progesterone. The binding of Sp1 to the Sp1-1 site has previously
been demonstrated by Inoue et al. [18], whereas the interaction of
progesterone-bound PR with Sp1 and CBP/p300 has been shown by
Owen et al. [15] by co-immunoprecipitation. In addition to PR, p300
can bind Sp1 as well as components of the basal transcription
machinery through distinct regions [15,32].
Fig. 6. Loss of p27 predicts poor outcome in breast cancer patients. (A) Ana
p27 mRNA levels were measured by quantitative RT-PCR in 91 breast tum
levels obtained in T-47D cells. The number of tumor samples with a given leve
mammary gland were 287% of its levels in T-47D cells (100%). (B) OS acco
relative to the p27 normalized mRNA expression are shown, with the lower
found in p27 mRNA-positive patients.
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PR levels and is a prognostic indicator of lower tumor
aggressiveness
To start assessing the putative patho-physiological relevance
of these in vitro data, we analyzed possible correlations be-
tween p27 mRNA levels and classical clinical, histological
and biological prognostic factors in 91 primary human breast
cancer biopsies. Interestingly, the expression level of p27 did
not follow a Gaussian curve, since the median value of p27
mRNA levels (22%) was lower than the mean value (30%), sug-
gesting that tumor incidence is inversely related to p27 gene
expression levels (Fig. 6A). Moreover, consistent with the abil-
ity of PR to trans-activate p27 in vitro, p27 transcript levels
correlated positively with PR levels (P = 0.01, r = 0.273, Table
1). p27 Gene expression also correlated positively to the
expression status of ER which is also a predictive marker of
good recovery [2], whereas it was negatively associated withlysis of CDKI p27 mRNA expression in human breast cancer biopsies.
or biopsies and were arbitrarily expressed as percentage relative to the
l of p27 mRNA is shown in the y-axis. p27 mRNA levels in the normal
rding to the presence of p27 mRNA. The Kaplan–Meier plots of OS
quartile as clinical positive threshold. A longer OS (overall survival) is
Table 1
Correlation (Spearman test) between normalized expression of p27 or
p21 and clinical, histological and biological parameters
p27 p21
Parameters P r P r
HPG 0.041 0.226 NS
Node involvement NS NS
Tumor size NS NS
ER <0.001 0.36 NS
PR 0.01 0.273 NS
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criteria such as cell diﬀerentiation, mitotic activity and the de-
gree of nuclear polymorphism, allowing classiﬁcation of tu-
mors from best (HPG 1) to worst prognosis (HPG 3) [22]
(Table 1). These data indicate that p27 gene expression may
negatively inﬂuence tumor formation and development in hu-
mans. Correlating with this, survival curves achieved by the
Kaplan–Meier method revealed that, as with PR [2], high
p27 mRNA levels (i.e., above the lower quartile) are associated
with a longer OS (overall survival) (P = 0.029) (Fig. 6B).
Since the growth-inhibitory eﬀects of progesterone on T-47D
cells is also related to the upregulation of protein expression of
the CDKI p21 [7,8] through a transcriptional mechanism [15],
we further analyzed whether p21 mRNA levels are also related
to a good recovery. However, p21 gene expression was not cor-
related with any of the classic prognostic parameters analyzed,
including PR (Table 1), and did not have a prognostic value in
primary breast cancer (data not shown).4. Discussion
In the present study, we ﬁrstly demonstrated by studying the
mammary carcinoma PR-positive T-47D cell line – which rep-
resents a relevant model to evaluate in vitro the progesterone
signalling in breast cancer cells [7,8,19] – that progesterone
upregulates p27 expression at the transcriptional level and that
this induction of p27 is required for the growth-inhibitory ac-
tion of progesterone. Interestingly, silencing of p27 expression
in T-47D cells did not signiﬁcantly aﬀect the basal cell growth
measured 4-days after the initiation of the siRNA treatment
(Fig. 1). This is possibly due to the induction of compensatory
mechanisms and/or the fact that in these untreated cancer cells,
basal levels of Cip/Kip proteins do not eﬀectively inhibit cell-
cycle progression [23]. By contrast, the response to progester-
one requires the induction of p27 levels which may reach the
threshold necessary for the inhibition of cyclin E/CDK2 com-
plexes. Further, in vitro analyses of the molecular mechanisms
involved indicated that, similarly as for p21 [15], progesterone-
activated PR induces the p27 gene promoter activity by
interacting with CBP/p300 and the transcription factor Sp1
at proximal Sp1-binding sites. Finally, we demonstrated in a
pilot study using human breast cancer biopsies that p27, but
not p21, gene expression levels are signiﬁcantly associated with
PR levels. This concurred with the requirement of p27 in the
response to progesterone observed in vitro. Interestingly, prox-
imal Sp1-binding sites have been previously shown to mediate
the p27-induction by other factors and steroid hormones
[18,20,21]. Thus, interactions formed between Sp1 and nuclear
receptors at this proximal region of the p27 promoter could
play a critical role in the convergence and integration ofmultiple signals to regulate p27 promoter activity (e.g., by
modulating Sp1 tethering to the p27 gene promoter) and thus
determine breast cancer cell fate.
p27 protein levels assessed by immunohistochemical or
immunocytological staining in primary breast cancer tissues
are associated with a favorable outcome, and their analysis
as a diagnostic complement and prognostic marker has been
thoroughly evaluated [24–26]. In clinical practice, consider-
ing that hormone receptor-positive tumors with low p27 lev-
els respond poorly to anti-estrogen therapy, the scoring of
p27 has been suggested to better determine therapeutic strat-
egies [27]. To date, post-translational modiﬁcations of p27
have been proposed as major mechanisms underlying the
regulation of p27 levels in human tumors [27]. In fact, mito-
gen-induced downregulation of p27 through ubiquitin-medi-
ated degradation and proteolytic processing during the G1
phase has been shown to regulate p27 protein levels and
consequently result in the activation of cyclin/CDK com-
plexes [28,29]. Furthermore, alterations in the proteasome-
mediated degradation pathways which govern p27 protein
levels and activity have been involved in the loss of p27 pro-
tein expression in certain breast tumors [25,30]. Interestingly,
our results from the pilot study further demonstrate that p27
(and not p21) mRNA levels also have an intrinsic prognostic
value in breast cancer. If conﬁrmed by larger prospective
studies, this observation suggests that, although the p27 gene
is rarely mutated [27], (dys)regulation of p27 promoter activ-
ity is associated with breast cancer development. It would
now be relevant to analyze whether methylation of CpG is-
land(s) in the p27 promoter is related to the loss of p27 gene
expression and the genesis of breast cancer, as previously
shown in malignant melanomas [31]. On the other hand,
considering the positive correlation between PR protein
and p27 gene expression in human breast tumors, it appears
that an alteration of activity of certain transcriptional fac-
tors – such as PR – regulating the p27 promoter, could also
play a role in mammary tumorigenesis.
In conclusion, the present data identify a role for PR in
the transcriptional control of the p27 gene which is corrob-
orated by the correlation between PR protein and p27
mRNA levels in human mammary tumors. PR does not di-
rectly bind to a canonical PRE (progesterone responsive ele-
ment), but interacts instead with the transcription factor Sp1
and general co-regulators (e.g., CBP/p300) resulting in the
formation of a multiprotein complex at proximal Sp1-bind-
ing sites of the p27 promoter (Fig. 5). Moreover, despite
the transcriptional regulation of both CDKIs p27 and p21
by progesterone, p21 mRNA levels did not correlate with
PR expression in breast tumors. Finally, p27, but not p21,
gene expression levels were signiﬁcantly associated with a
lower aggressiveness of breast tumors and with a good prog-
nosis. Therefore, molecules selectively inducing p27 gene
expression (e.g., selective PR modulators characterized by
their ability to induce PR/p300 recruitment to the p27 pro-
moter) could be a promising way of identifying new drugs
for HRTs, oral contraceptives and/or treatment of breast
cancer.Acknowledgments: The authors thank Dr. D. Monte´ (IBL, France) and
Dr. T. Sakai (Kyoto Prefectural University of Medicine, Japan) for the
kind gift of the pcDNA3-Sp1 expression and the human p27 gene lucif-
erase reporter plasmids, respectively.
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